Research

By Todd Ackerman                                                                           Nov. 5, 2014

... researchers at the University of Texas-Austin have developed a nasal spray vaccine that has protected monkeys against the deadly Ebola virus even a year after immunization.

The vaccine, a genetically engineered cold virus containing a tiny portion of Ebola DNA, saved 100 percent of monkeys who got a single spray through the nose in a new UT study. Injecting the vaccine only saved the lives of about 50 percent.

"The main advantage is the long-lasting protection after a single inhaled dose," Maria Croyle, a  professor of pharmaceutics and the study's principal investigator, said in a statement. "This is important since the longevity of other vaccines for Ebola (hasn't been) fully evaluated....

TORONTO GLOBE AND MAIL                               Nov. 3, 2014
By Kelly Grant
Canada is spending another $30.5-million to fight Ebola, but Ottawa is still not answering pleas from international aid organizations for medical personnel to care for the ill in West Africa.

The bulk of the money announced on Monday – $23.5-million – will be spent on testing a Canadian vaccine and an experimental therapy, ZMapp, both of which were developed largely at the National Microbiology Lab in Winnipeg....

A lab technician at the National Microbiology Lab in Winnipeg, Manitoba November 3, 2014.
(LYLE STAFFORD/THE CANADIAN PRESS)

Canada has so far dispatched two mobile laboratories with rotating teams of scientists to rapidly diagnose or rule out Ebola in Sierra Leone.

But Ottawa has been reluctant to send medical staff to West Africa because the government cannot guarantee they could be airlifted out if they fall ill.

WALL STREET JOURNAL                             Nov 3, 2014

By Amy Dockser Marcus

In the search for answers about Ebola, researchers are starting to look at an unexpected group of people: parents of children who have the rare but fatal genetic disease Niemann-Pick Type C.

Blood and tissue samples from Hugh and Chris Hempel of Reno, Nev., whose children have a rare disease, may help in ongoing Ebola research. Hempel family

The intersection between research in Ebola and NPC disease was surprising, and came after two scientific papers were published in 2011 demonstrating that a protein made by the same gene related to NPC disease is essential for Ebola infection.

Ebola uses the so-called NPC1 protein made by the gene to get into the cell and replicate the virus.

Now, research suggests that the gene that causes NPC disease may also offer protection against Ebola.

Read complete story:
http://online.wsj.com/articles/researchers-study-ebola-link-to-gene-in-rare-disease-1414965218

Overview of what still needs to be learned about the Ebola virus

Research studies have suggested at least three potential paths through which the Ebola virus can invade tissues. Credit Photograph by the C.D.C. via Getty Images

THE NEW YORKER                                      Nov. 1, 2014

By Jerome Groopman

...there are still serious gaps in what we know about the biology of Ebola, and that ignorance inhibits us from preventing future outbreaks and reducing death rates that still exceed seventy per cent. We don’t know enough about the biology of Ebola to bring the outbreak under full control, or to neutralize the virus once the outbreak is contained. Between on-the-ground efforts and advances in science, we need a balanced approach.

Read complete article